Business Context and Reporting Period
This Form 8-K was filed by Nemus Bioscience, Inc. (noted as Skye Bioscience, Inc. in metadata) on February 1, 2019. The report details a second drawdown under a Multi Draw Credit Agreement with Emerald Health Sciences Inc. intended for general corporate and working capital purposes.
Key Financial Metrics
- Drawdown Amount: $2,000,000.
- Total Outstanding Principal: $4,000,000 (as of February 1, 2019).
- Facility Limit: $20,000,000 revolving credit facility.
- Interest Rate: 7% per annum.
- Maturity Date: October 5, 2022.
- Collateral: Unsecured.
Material Changes and Equity Implications
The filing reports a material increase in debt obligations and potential equity dilution:
- Debt Conversion: The $2,000,000 drawdown is convertible into 5,000,000 shares of common stock at a fixed price of $0.40 per share.
- Warrant Issuance: The company issued a warrant to purchase up to 2,500,000 shares at an exercise price of $0.50 per share. The warrant expires on the fifth anniversary of issuance.
- Default Provisions: Upon an Event of Default, the entire outstanding principal and accrued interest become immediately due and payable.
Guidance, Risks, and Contingencies
The filing does not provide specific financial guidance or management commentary beyond the transaction details. Key risks include:
- Liquidity Risk: The debt is unsecured and subject to immediate acceleration upon default.
- Dilution Risk: Significant potential dilution exists if the lender exercises conversion rights or warrant options.
- Regulatory Status: The issuance of convertible securities and warrants was exempt from registration under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D.
Investor Verification Checklist
- Verify the company's current cash position to assess the necessity of this drawdown.
- Review the full Credit Agreement (Exhibit 10.1 from the October 12, 2018 filing) for specific definitions of "Event of Default."
- Monitor the company's stock price relative to the $0.40 conversion price and $0.50 warrant exercise price to gauge dilution likelihood.
- Confirm the total remaining availability under the $20,000,000 credit facility.